organization · Reporting owner
Forbion Growth III Management B.V.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braveheart Bio, Inc.BRVE · Entity 4564 | 10% owner | August 07, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braveheart Bio, Inc.
Report date August 07, 2026 · Filed August 07, 2026
Jointly reported with Forbion Growth Opportunities Fund III Cooperatief U.A., Forbion Ventures Fund VII Cooperatief U.A., Forbion Ventures VII Management B.V.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,640,546 |
Last balance in matching sequence
After 2026-08-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-07 · Conversion · Acquired 9,132,420 · Balance 9,720,546 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F2: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Row 3 · 2026-08-07 · Purchase · Acquired 1,920,000 · Balance 11,640,546 F2: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Forbion Ventures Fund VII Cooperatief U.A. | 10,185,478 |
Last balance in matching sequence
After 2026-08-07 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-08-07 · Conversion · Acquired 7,990,867 · Balance 8,505,478 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F3: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Row 4 · 2026-08-07 · Purchase · Acquired 1,680,000 · Balance 10,185,478 F3: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-07 · Conversion · Disposed 40,000,000 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F2: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Forbion Ventures Fund VII Cooperatief U.A. | 0 |
Reported balance
After 2026-08-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-07 · Conversion · Disposed 35,000,000 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F3: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.
F2: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
F3: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionSeries A Preferred Stock · Derivative | 35,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · derivative · entry 6 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Forbion Ventures Fund VII Cooperatief U.A. Disclosed balance after: 0 Underlying: Common Stock · 7,990,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F3 · ownership.nature: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionSeries A Preferred Stock · Derivative | 40,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · derivative · entry 5 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,132,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F2 · ownership.direct: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | PurchaseCommon Stock | 1,680,000 | $18.00 | $30,240,000.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · nonDerivative · entry 4 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Forbion Ventures Fund VII Cooperatief U.A. Disclosed balance after: 10,185,478 F3 · ownership.nature: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | PurchaseCommon Stock | 1,920,000 | $18.00 | $34,560,000.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · nonDerivative · entry 3 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,640,546 F2 · ownership.direct: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionCommon Stock | 7,990,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · nonDerivative · entry 2 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Forbion Ventures Fund VII Cooperatief U.A. Disclosed balance after: 8,505,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F3 · ownership.nature: Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 21:25 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionCommon Stock | 9,132,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-340528 · ownership.xml · nonDerivative · entry 1 Forbion Growth Opportunities Fund III Cooperatief U.A. · CIK 0002050895 · 10% owner Forbion Growth III Management B.V. · CIK 0002050893 · 10% owner Forbion Ventures Fund VII Cooperatief U.A. · CIK 0002148128 · 10% owner Forbion Ventures VII Management B.V. · CIK 0002148132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,720,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date. F2 · ownership.direct: Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.